VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: A 2013 update

Pharmacogenomics

Volumn 14, Issue 13, 2013, Pages 1659-1667

  Eng, Lawson ^a,b   Liu, Geoffrey ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

angiogenesis; bevacizumab; cancer; outcomes; polymorphisms; predictive markers; prognostic markers; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN A;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE FUNCTION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTION; REVIEW; STOMACH CANCER; TUMOR VASCULARIZATION; VEGF GENE;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885410664     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.165     Document Type: Review

References (81)

1. Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A. Anti-angiogenesis and angioprevention: Mechanisms, problems and perspectives. Cancer Detect. Prev. 27(3), 229-238 (2003).
2. Norrby K. In vivo models of angiogenesis. J. Cell. Mol. Med. 10(3), 588-612 (2006).
3. Su MT, Lin SH, Lee IW, Chen YC, Kuo PL. Association of polymorphisms/haplotypes of the genes encoding vascular endothelial growth factor and its KDR receptor with recurrent pregnancy loss. Hum. Reprod. 26(4), 758-764 (2011).
4. Shibuya M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 153(1), 13-19 (2013).
5. Kahlon R, Shapero J, Gotlieb AI. Angiogenesis in atherosclerosis. Can. J. Cardiol. 8(1), 60-64 (1992).
6. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3(6), 401-410 (2003).
7. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti-and pro-angiogenic therapies. Genes Cancer 2(12), 1097-1105 (2011).
8. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol. Pharm. Bull. 34(12), 1785-1788 (2011).
9. Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol. Dis. 39(2), 212-220 (2007). International HapMap Consortium;
10. Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
11. Hochberg EP, Miklos DB, Neuberg D et al. A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood 101(1), 363-369 (2003).
12. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. 107(2), 155-176 (2005).
13. Eng L, Ibrahim-zada I, Jarjanazi H et al. Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. BMC Med. Genomics 4, 18 (2011).
14. Reich DE, Cargill M, Bolk S et al. Linkage disequilibrium in the human genome. Nature 411(6834), 199-204 (2001).
15. Eng L, Azad AK, Habbous S et al. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: A systematic review and meta-analysis. Clin. Cancer Res. 18(17), 4526-4537 (2012). Includes tables that summarize many of the manuscripts discussed and evaluated in the current article, and is the systematic review and meta-analysis that this current update is based upon.
16. Jain L, Vargo CA, Danesi R et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol. Cancer Ther. 8(9), 2496-2508 (2009).
17. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J. 13(1), 1-11 (2013).
18. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J. Clin. Oncol. 28(26), 4029-4037 (2010).
19. Hayman SR, Leung N, Grande JP, Garovic VD. VEGF inhibition, hypertension, and renal toxicity. Curr. Oncol. Rep. 14(4), 285-294 (2012).
20. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann. Pharmacother. 43(3), 490-501 (2009).
21. Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol. 13(10), e427-e436 (2012). Discusses the state of affairs with respect to pharmacogenetic biomarkers for antiangiogenic therapies, some of the strengths and pitfalls of a number of these biomarkers and also provides the authors? own discussion on the future directions in the field.
22. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat. Rev. 36(7), 550-556 (2010).
23. Conley BA, Taube SE. Prognostic and predictive markers in cancer. Dis. Markers 20(2), 35-43 (2004).
24. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672-4678 (2008).
25. Formica V, Palmirotta R, Del Monte G et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int. J. Colorectal Dis. 26(2), 143-151 (2011).
26. Argiris A, Karamouzis MV, Gooding WE et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J. Clin. Oncol. 29(9), 1140-1145 (2011).
27. Loupakis F, Ruzzo A, Salvatore L et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11, 247 (2011).
28. Smerdel MP, Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol. Oncol. 118(2), 167-171 (2010).
29. Etienne-Grimaldi MC, Formento P, Degeorges A et al. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br. J. Clin. Pharmacol. 71(6), 921-928 (2011).
30. Zhang W, Azuma M, Lurje G et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res. 30(10), 4209-4217 (2010).
31. Schultheis AM, Lurje G, Rhodes KE et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 14(22), 7554-7563 (2008).
32. Jain L, Sissung TM, Danesi R et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J. Exp. Clin. Cancer Res. 29, 95 (2010).
33. Sakaeda T, Yamamori M, Kuwahara A et al. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther. Drug Monit. 30(4), 497-503 (2008).
34. Balasubramanian SP, Cox A, Cross SS, Higham SE, Brown NJ, Reed MW. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int. J. Cancer 121(5), 1009-1016 (2007).
35. Lu H, Shu XO, Cui Y et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 65(12), 5015-5019 (2005).
36. Kidd LR, Brock GN, VanCleave TT et al. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival. Cancer Causes Control 21(10), 1545-1557 (2010).
37. Lurje G, Zhang W, Schultheis AM et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann. Oncol. 19(10), 1734-1741 (2008).
38. Dassoulas K, Gazouli M, Rizos S et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol. Carcinog. 48(6), 563-569 (2009).
39. Kim JG, Chae YS, Sohn SK et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin. Cancer Res. 14(1), 62-66 (2008).
40. Zhang W, Gordon M, Press OA et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet. Genomics 16(7), 475-483 (2006).
41. Hansen TF, Garm Spindler KL, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J. 11(1), 53-60 (2011).
42. Vidaurreta M, Sanchez-Munoz R, Veganzones S et al. Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer. Rev. Esp. Enferm. Dig. 102(1), 20-31 (2010).
43. Bradbury PA, Zhai R, Ma C et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin. Cancer Res. 15(14), 4680-4685 (2009).
44. Lorenzen S, Panzram B, Keller G et al. Association of the VEGF 936CT polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. Mol. Imaging Biol. 13(1), 178-186 (2011).
45. Lurje G, Leers JM, Pohl A et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann. Surg. 251(5), 857-864 (2010).
46. Tzanakis N, Gazouli M, Rallis G et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J. Surg. Oncol. 94(7), 624-630 (2006).
47. Al-Moundhri MS, Al-Nabhani M, Burney IA, Al-Farsi AA, Al-Bahrani B. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-A case-control study in an Omani population. Mol. Carcinog. 48(12), 1170-1176 (2009).
48. Kim JG, Sohn SK, Chae YS et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann. Oncol. 18(6), 1030-1036 (2007).
49. Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. J. Exp. Clin. Cancer Res. 28, 94 (2009).
50. Lurje G, Husain H, Power DG et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann. Oncol. 21(1), 78-86 (2010).
51. Stocker G, Ott K, Henningsen N et al. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur. J. Cancer 45(18), 3326-3335 (2009).
52. Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur. Urol. 52(4), 1147-1155 (2007).
53. Kim EJ, Jeong P, Quan C et al. Genotypes of TNF-a, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer. Urology 65(1), 70-75 (2005).
54. Mucci LA, Stark JR, Figg WD et al. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. Int. J. Cancer 125, 1143-1146 (2009).
55. Li HC, Cai QY, Shinohara ET et al. Endostatin polymorphism 4349G/A(D104N) is not associated with aggressiveness of disease in prostate [corrected] cancer. Dis. Markers 21, 37-41 (2005).
56. Amano M, Yoshida S, Kennedy S et al. Association study of vascular endothelial growth factor gene polymorphisms in endometrial carcinomas in a Japanese population. Eur. J. Gynaecol. Oncol. 29(4), 333-337 (2008).
57. Lose F, Nagle CM, O?Mara T et al. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol. Oncol. 119(3), 479-483 (2010).
58. Goode EL, Maurer MJ, Sellers TA et al. Inherited determinants of ovarian cancer survival. Clin. Cancer Res. 16(3), 995-1007 (2010).
59. Hefler LA, Mustea A, Konsgen D et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin. Cancer Res. 13, 898-901 (2007).
60. Polterauer S, Grimm C, Mustea A et al. Vascular endothelial growth factor gene polymorphisms in ovarian cancer. Gynecol. Oncol. 105, 385-389 (2007).
61. Smerdel MP, Waldstrom M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int. J. Gynecol. Cancer 19, 578-584 (2009).
62. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol. Oncol. 117, 109-116 (2010).
63. Kim YH, Kim MA, Park IA et al. VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival. Gynecol. Oncol. 119, 232-236 (2010).
64. Heist RS, Zhai R, Liu G et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J. Clin. Oncol. 26(6), 856-862 (2008).
65. Guan X, Yin M, Wei Q et al. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10, 431 (2010).
66. Dong J, Dai J, Shu Y et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 31(6), 1080-1086 (2010).
67. Masago K, Fujita S, Kim YH et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci. 100(10), 1917-1922 (2009).
68. Perren TJ, Swart AM, Pfisterer J et al. A Phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365(26), 2484-2496
69. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365(26), 2473-2483 (2011). Along with [68], this is one of the two Phase III trials that may undergo pharmacogenenetic analysis in the coming years.
70. Dhillon S. Bevacizumab combination therapy: For the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Drugs 72(7), 917-930 (2012).
71. Oh SY, Kwon HC, Kim SH et al. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer 13, 43 (2013).
72. Dan S, Bai L, Li-Jie W, Ting Z, Zhi-Yuan M. Pharmacogenetic angiogenesis profiling for first-line chemotherapy in patients with advanced gastric cancer. Cancer Invest. doi:10. 3109/07357907.2013.795580 (2013) (Epub ahead of print).
73. Beuselinck B, Karadimou A, Lambrechts D et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 108(4), 887-900 (2013).
74. Beuselinck B, Karadimou A, Lambrechts D et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib-A multicentric retrospective analysis. Acta Oncol. doi:10.310 9/0284186X.2013.770600 (2013) (Epub ahead of print).
75. Scartozzi M, Bianconi M, Faloppi L et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br. J. Cancer 108(5), 1126-1132 (2013).
76. Schutz FA, Pomerantz MM, Gray KP et al. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: A cohort study. Lancet Oncol. 14(1), 81-87 (2013).
77. Miles DW, De Haas SL, Dirix LY et al. Biomarker results from the AVADO Phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br. J. Cancer 108(5), 1052-1060 (2013).
78. Uzunoglu FG, Yavari N, Bohn BA et al. C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC. Lung Cancer 81(1), 123-129 (2013).
79. Dy GK, Mandrekar SJ, Nelson GD et al. A randomized Phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J. Thorac. Oncol. 8(1), 79-88 (2013).
80. Morita S, Uehara K, Nakayama G et al. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Cancer Chemother. Pharmacol. 71(2), 405-411 (2013).
81. Dong H, Wang S. Exploring the cancer genome in the era of next-generation sequencing. Front. Med. 6(1), 48-55 (2012).